Annual Reports

  • 10-K (Feb 24, 2011)
  • 10-K (Mar 2, 2010)
  • 10-K (Feb 26, 2009)
  • 10-K (Feb 28, 2008)
  • 10-K (Feb 26, 2008)
  • 10-K (Feb 28, 2007)

 
Quarterly Reports

 
8-K

 
Other

Human Genome Sciences 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99
  3. Graphic
  4. Graphic
8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 27, 2012

 

 

 

HUMAN GENOME SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-14169   22-3178468

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

14200 Shady Grove Road, Rockville, Maryland 20850-7464

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (301) 309-8504

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Section 2 — Financial Information

Item 2.02. Results of Operations and Financial Condition.

On February 27, 2012, Human Genome Sciences, Inc. issued a press release announcing its financial results for the quarter and full year ended December 30, 2011. A copy of the release is furnished as Exhibit 99 to this Current Report on Form 8-K.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

99    Press Release dated February 27, 2012


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HUMAN GENOME SCIENCES, INC.
By:   /s/ James H. Davis, Ph.D.        
  Name:   James H. Davis, Ph.D.
  Title:   Executive Vice President, General Counsel and Secretary

Date: February 27, 2012


INDEX TO EXHIBITS

 

Exhibit No.

  

Description

Exhibit 99    Press Release dated February 27, 2012.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki